Bottoms L,Pons MP,Fineberg NA,Pellegrini L,Fox A,Wellsted D .2022 .of exercise on obsessivecompulsive disorder symptoms: A systematic review and meta-analysis. Int J Psychiatry Clin, 2151474(3) : 232-42.
de la Cruz LF,Isomura K,Lichtenstein P,Ruck C,Cols DM .2022 .Morbidity and mortality in obsessive-compulsive disorder: A narrative review. Neurosci Biobehav Rev, 104602 : 104602.
Cervin M. .2022 .Obsessive-compulsive disorder: Diagnosis, clinical features, nosology, and epidemiology. Psychiatric Clin North Am, 10(1) : 1-6.
Xie L,Hu P,Guo Z,Chen M,Wang X,Du X .2024 .Immediate and long-term e cacy of transcranial direct stimulation (tCDS) in obsessive-compulsive disorder, posttraumatic stress disorder and anxiety disorders: A systematic review and meta-analysis. Transl Psychiatry, 10(1) : 343.
Biria M,Banca P,Healy MP,Keser E,Sawiak SJ,Rodgers CT .2023 .Cortical glutamate and GABA are related to compulsive behaviour in individuals with obsessive compulsive disorder and healthy controls. Nat Commun, 10(1) : 3324.
Chohan MO,Kopelman JM,Yueh H,Fazlali Z,Greene N,Harris AZ .2022 .Developmental impact of glutamate transporter overexpression on dopaminergic neuron activity and stereotypic behavior. Mol Psychiatry, 10(3) : 1515-26.
Vlcek P,Polak J,Brunovsky M,Horacek J .2018 .Role of glutamatergic system in obsessive-compulsive disorder with possible therapeutic implications. Pharmacopsychiatry, 10(6) : 229-42.
Pittenger C .2015 .Glutamate modulators in the treatment of obsessive-compulsive disorder. Psychiatric Ann, 10(6) : 00485713-15.
Escobar AP,Wendland JR,Chavez AE,Moya PR .2019 .The neuronal glutamate transporter EAAT3 in obsessive-compulsive disorder. Front Pharmacol, 01362 : 1362.
Bufan B,Curuvija I,Blagojevic V,Milanovic JG,Prijic I,Radosavljevic T .2024 .NMDA receptor antagonist memantine ameliorates experimental autoimmune encephalomyelitis in aged rats. Biomedicines, 10(4) : 717.
Elnaiem W,Benmelouka AY,Elgendy AMN,Abdelgalil MS,Alsaman MZB,Mogheeth A .2022 .Evaluation of memantine's e cacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis. Hum Psychopharmacol, 10(5) : .
Shah NM,Ghazaryan N,Gonzaga NL,Paclibar CG,Biju AP,Liang C .2023 .Glutamate's e ects on the N-Methyl-D-aspartate (NMDA) receptor ion channel in alzheimer's disease brain: Challenges for PET radiotracer development for imaging the NMDA ion channel. Molecules, 10(1) : 20.
Bakhla AK,Verma V,Soren S,Sarkhel S,Chaudhury S. .2013 .An open-label trial of memantine in treatment-resistant obsessivecompulsive disorder. Ind Psychiatry J, 10(2) : 132930-6748.
.2023 .trichotillomania and skin-picking disorder. Am J Psychiatry, 20220737(5) : 348-56.
Kishi T,Matsuda Y,Iwata N. .2018 .Combination therapy of serotonin reuptake inhibitors and memantine for obsessivecompulsive disorder: A meta-analysis of double-blind, randomized, placebo-controlled trials. J Alzheimer's Dis, 10(1) : 43-8.
Modarresi A,Chaibakhsh S,Koulaeinejad N,Koupaei SR .2019 .A current systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res, 112602 : 112602.
Hadi F,Kamalzadeh S,Hoobehfekr Shalbafan M. L .2021 .Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: A systematic review and meta-analysis. BMC Pharmacol Toxicol, 10(1) : 69.
Moher D,Shamseer L,Clarke M,Ghersi D,Liberati A,Petticrew M .2015 .4(1):1. Sys Rev, 10 : .
Hauschildt M,Dar R,Schroder J,Moritz S. Congruence .2019 .and discrepancy between self-rated and clinician-rated symptom severity on the yale-brown obsessive-compulsive scale (YBOCS) before and after a low-intensity intervention. Psychiatry Res, 01 : 595-602.
Yan J,Gu Y,Wang M,Cui Y,Li Y. .2022 .The obsessive-compulsive symptoms in tic disorders and the psychometric properties of children's yale-brown obsessive-compulsive scale: An evidence-based survey in a Chinese sample. Front Pediatr, 794188 : 794188.
Feingold .2009 .A. E ect sizes for growth-modeling analysis for controlled clinical trials in the same metric as for classical analysis. Psychol Methods, 10(1) : 43-53.
Jun L .2019 .E cacy and tolerability of memantine in refractory obsessive-compulsive disorder. J Int Psychiatry, 02(02) : 266-9.
Sahraian A,Jahromi LR,Ghanizadeh A,Mowla A .2017 .Memantine as an adjuvant treatment for obsessive compulsive symptoms in manic phase of bipolar disorder: A randomized, double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol, 10(2) : 246-9.
Modarresi A,Sayyah M,Razooghi S,Eslami K,Javadi M,Kouti L M .2018 .Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: A randomized controlled trial. Pharmacopsychiatry, 10(6) : 263-9.
Haghighi M,Jahangard L,Beigi HM,Bajoghli H,Hafezian H,Rahimi A .2013 .In a double-blind, randomized and placebocontrolled trial, adjuvant memantine improved symptoms in inpatients su ering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl), 10(4) : 633-40.
Grant JE,Chesivoir E,Valle S,Ehsan D,Chamberlain SR . .Double-blind placebo-controlled study of memantine in. , : .
Ghaleiha A,Entezari N,Modabbernia A,Najand B,Askari N,Tabrizi M .2012 .Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study. J Psychiatr Res, 09(2) : 175-80.
Farnia V,Gharehbaghi H,Alikhani M,Almasi A,Golshani S,Tatari F .2018 .and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: Double-blind, randomized, placebo-controlled trial. J Psychiatr Res, 07 : 137-43.
Askari S,Mokhtari S,Shariat SV,Shariati B,Yarahmadi M,Shalbafan M. .2022 .Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial. BMC Psychiatry, 10(1) : 34.
Targa L,Mottarlini G,Thielens F,Rizzi S,Villers B,A B .2024 .Memantine-induced functional rewiring of the glutamate synapse in the striatum of dopamine transporter knockout rats. Br J Pharmacol, 10(6) : 1377-93.
Marinova Z,Chuang DM,Fineberg N DM .2017 .Glutamate-modulating drugs as a potential therapeutic strategy in obsessivecompulsive disorder. Curr Neuropharmacol, 10(7) : 977-95.
Norman LJ,Carlisi CO,Christakou A,Cubillo A,Murphy CM,Chantiluke K .2017 .Shared and disorder-speci c task-positive and default mode network dysfunctions during sustained attention in paediatric attention-de cit/ hyperactivity disorder and obsessive/compulsive disorder. NeuroImage Clin, 04 : 181-93.
Beucke JC,Sepulcre J,Talukdar T,Linnman C,Zschenderlein K,Endrass T .2013 .Abnormally high degree connectivity of the orbitofrontal cortex in obsessive-compulsive disorder. JAMA Psychiatry, 173(6) : 619-29.
Starkiewicz AC,Noworyta K,Solich J,Korlatowicz A,Gorecka AF,Rygula R .2024 .Identi cation of genes regulated by sensitivity to negative feedback and prolonged alcohol consumption in rats. Pharmacol Rep, 10(1) : 207-15.
Netto VM,Flores CA,Pallanti S. .2020 .Pharmacological treatment for comorbid bipolar disorder and obsessive-compulsive disorder in adults. J Psychiatr Pract, 10(5) : 383-93.